111 |
The Biolimus A9 DES Program (Focus on Stealth 1) |
Eberhard Grube |
Jun. 10. 05 |
110 |
The Endeavor DES Program (Focus on Endeavor 2) |
Richard E. Kuntz |
Jun. 10. 05 |
109 |
Recent Updates from the Cypher Trials (Cypher Meta-Analysis, Diabetes, Late FU from FIM and SIRIUS, ARTS II) |
Alexandre Abizaid |
Jun. 03. 05 |
108 |
Recent Updates from the Taxus Trials (Taxus 2 and 4 Late FU, Taxus Meta-Analysis, and Taxus 5) |
Gregg W. Stone |
Jun. 03. 05 |
107 |
DES Pathobiology Considerations: What We Know and What We Don't Know Can Hurt Us! |
Renu Virmani |
May. 27. 05 |
106 |
Late Loss Remains the Best Single Indicator of DES Performance |
Richard E. Kuntz |
May. 27. 05 |
105 |
Is the TAXUS Stent Benefit Extended to the Most Complicated Patients and Lesions? |
Eberhard Grube |
May. 27. 05 |
104 |
New Drug Eluting Stents |
Alexandre Abizaid |
May. 20. 05 |
103 |
Are All Sirolimus Analogs Alike? |
Robert Falotico |
May. 20. 05 |
102 |
Paclitaxel-Eluting TAXUS Stents Strengths and Weaknesses |
Gregg W. Stone |
May. 13. 05 |